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Visual Abstract
IMPORTANCE Depression is a major cause of disability worldwide. Although empirically

Multimedia

supported treatments are available, there is scarce evidence on how to effectively
personalize psychological treatment selection.

Supplemental content

OBJECTIVE To compare the clinical effectiveness and cost-effectiveness of 2 treatment

selection strategies: stepped care and stratified care.
DESIGN, SETTING, AND PARTICIPANTS This multisite, cluster randomized clinical trial recruited
participants from the English National Health Service from July 5, 2018, to February 1, 2019.
Thirty clinicians working across 4 psychological therapy services were randomly assigned to
provide stratified (n = 15) or stepped (n = 15) care. In stepped care, patients sequentially
access low-intensity guided self-help followed by high-intensity psychotherapy. In stratified
care, patients are matched with either low- or high-intensity treatments at initial assessment.
Data were analyzed from May 18, 2020, to October 13, 2021, using intention-to-treat
principles.
INTERVENTIONS All clinicians used the same interview schedule to conduct initial
assessments with patients seeking psychological treatment for common mental disorders,
but those in the stratified care group received a personalized treatment recommendation for
each patient generated by a machine learning algorithm. Eligible patients received either
stratified or stepped care (ie, treatment as usual).
MAIN OUTCOMES AND MEASURES The preregistered outcome was posttreatment reliable and
clinically significant improvement (RCSI) of depression symptoms (measured using the
9-item Patient Health Questionnaire). The RCSI outcome was compared between groups
using logistic regression adjusted for baseline severity. Cost-effectiveness analyses compared
incremental costs and health outcomes of the 2 treatment pathways.
RESULTS A total of 951 patients were included (618 women among 950 with data available
[65.1%]; mean [SD] age, 38.27 [14.53] years). The proportion of cases of RCSI was
significantly higher in the stratified care arm compared with the stepped care arm (264 of
505 [52.3%] vs 134 of 297 [45.1%]; odds ratio, 1.40 [95% CI, 1.04-1.87]; P = .03). Stratified
care was associated with a higher mean additional cost per patient (£104.5 [95% CI,
£67.5-£141.6] [$139.83 (95% CI, $90.32-$189.48)]; P < .001) because more patients accessed
high-intensity treatments (332 of 583 [56.9%] vs 107 of 368 [29.1%]; χ2 = 70.51; P < .001),
but this additional cost resulted in an approximately 7% increase in the probability of RCSI.
CONCLUSIONS AND RELEVANCE In this cluster randomized clinical trial of adults with common
mental disorders, stratified care was efficacious and cost-effective for the treatment of
depression symptoms compared with stepped care. Stratified care can improve depression
treatment outcomes at a modest additional cost.
TRIAL REGISTRATION isrctn.org Identifier: ISRCTN11106183

Author Affiliations: Author
affiliations are listed at the end of this
article.

JAMA Psychiatry. doi:10.1001/jamapsychiatry.2021.3539
Published online December 8, 2021.

Corresponding Author: Jaime
Delgadillo, PhD, Clinical and Applied
Psychology Unit, Department of
Psychology, University of Sheffield,
1 Vicar Ln, Cathedral Court, Floor F,
Sheffield S1 2LT, United Kingdom
(jaime.delgadillo@nhs.net).

(Reprinted) E1

Downloaded From: https://jamanetwork.com/ by a Non-Human Traffic (NHT) User on 01/07/2022

Research Original Investigation

C

linical guidelines for the management of depression recommend psychological interventions organized in a
stepped care model, in which most patients access only
low-intensity treatments such as guided self-help, and patients who remain symptomatic after this step can access more
intensive and costly psychotherapies such as cognitive behavioral therapy.1 Systematic reviews of clinical trials indicate that
stepped care results in improved effect sizes (Cohen d = 0.34)2
and higher odds of recovery (odds ratio [OR], 1.31 [IQR,
1.05-1.66])3 relative to usual care. In theory, stepped care is a
self-correcting model4 in which patients eventually receive an
appropriately intensive treatment for their needs. This model
widens access to care by offering the least restrictive and least
costly interventions to most people.5
Stepped care has been implemented at a national level in
England, through the Improving Access to Psychological Therapies (IAPT) program, which currently receives more than 1 million referrals per year.6 A systematic review of studies arising
from the IAPT program7 indicated that stepped care is generally associated with large pre- to posttreatment effect sizes for
depression (Cohen d = 0.87). However, these effects were attenuated in subgroups of patients with more complex
presentations,7 such as those with comorbid physical illnesses,8
personality disorder traits,9 disabilities,10 and low treatment
expectancies10 and those living in socioeconomically deprived circumstances.11 These complicating factors have a cumulative effect, such that patients with several of these features tend to have poorer treatment outcomes.10,12 On this
basis, some have argued that IAPT services should move toward a stratified approach to psychological treatment selection, which would involve matching the intensity of treatment to the level of complexity in each individual case.12
Stratified medicine aims to identify individuals who will
have the most clinical benefit or least harm from specific
treatments.13 Recent studies10,12,14,15 have indicated that stratified care has potential to improve the effectiveness of psychological care for depression. However, most of these studies
draw their conclusions from post hoc analyses of retrospective data, and the only prospective study16 was underpowered to test its primary hypothesis. Rigorous and adequately
powered experimental studies are necessary to determine
whether stratified care may be an effective and affordable way
to organize psychological interventions. To fill this evidence
gap, we conducted a cluster randomized clinical trial of stratified care vs stepped care in IAPT services. We hypothesized
that stratified care would improve depression treatment outcomes compared with stepped care and that this would be explained by higher improvement rates in complex cases matched
with high-intensity treatment.

Methods
Study Design
This pragmatic, multisite, single-blind, cluster randomized
clinical trial involved 4 IAPT services in northern England that
were managed by Lancashire and South Cumbria NHS
(National Health Service) Foundation Trust and Rotherham
E2
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Key Points
Question Is stratified care an efficacious and cost-effective
approach to psychological treatment selection compared with
stepped care?
Findings In this cluster randomized clinical trial of 951 adults with
common mental disorders, stratified care was efficacious and
cost-effective for the treatment of depression symptoms relative
to stepped care.
Meaning These findings suggest that stratified care has the
potential to improve depression treatment outcomes at a modest
incremental cost.

Doncaster and South Humber NHS Foundation Trust. These
services implemented stepped care in line with national
guidelines.1 The trial protocol (Supplement 1) was preregistered and was approved by a research ethics committee and
the Health Research Authority. This study followed the
Consolidated Standards of Reporting Trials (CONSORT)
reporting guideline.

Participants
The research team recruited clinicians after presenting the
study rationale at clinical team meetings. Interested clinicians provided written informed consent via email. Patients
seeking psychological treatment were recruited by participating clinicians using a standardized recruitment script at the
start of routine assessments that aimed to determine suitability for treatment in the IAPT program. Patients provided
verbal consent because assessments were conducted via
telephone.
Clinicians were included if they were psychological wellbeing practitioners who conducted initial assessments in the
participating services and were qualified with a nationally recognized postgraduate certificate in low-intensity psychological interventions (eMethods 1 in Supplement 2). Consenting
patients were eligible if they (1) sought treatment for a common mental disorder (unipolar depression, posttraumatic stress
disorder, obsessive-compulsive disorder, body dysmorphic disorder, phobias, and other anxiety disorders); (2) were deemed
suitable for treatment in the IAPT program according to clinical guidelines; and (3) accessed treatment, defined by attending at least 1 session after their initial assessment. Regarding
the second criterion, patients deemed unsuitable for treatment in this setting had severe mental disorders (eg, psychotic, bipolar), severe learning disabilities, substance dependence, acute suicidal risk, or problems not meeting criteria for
a common mental disorder.17 Patients were excluded from
these services and the study if they were already accessing psychological treatment elsewhere (ie, privately or through other
services). No other exclusion criteria were applied, and patients were eligible for participation regardless of their current use of medications or other medical interventions.

Randomization and Masking
Consenting clinicians were randomized to a stratified treatment group or a stepped care (treatment as usual) control group
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by an independent research assistant using a computergenerated 1:1 randomization schedule in blocks of 4, stratified by team. Randomization was clustered by clinicians to
minimize contamination bias that may occur if clinicians applied stratified care with some patients and stepped care with
others. Clinicians were therefore aware of their random allocation, which was communicated to them after randomization. Patients provided informed consent for clinicians to gather
assessment information, enter it into a computer system, and
use it to inform their treatment recommendation, but they were
blinded to the decision-making process that guided each of the
treatment groups.

Procedures
Assessment Interviews
All consenting patients were assessed by participating clinicians using the same semistructured interview schedule. These
were routine telephone-based assessments that lasted an average of 40 minutes and followed practice guidelines for IAPT
services.17 The assessments covered the patient’s presenting
problems and their impact, history, current life circumstances, and treatment goals. As part of this assessment, clinicians in both groups gathered clinical and demographic data
that were entered in a computerized application as part of the
study procedures. Race and ethnicity were self-reported by participants. Although they provided a self-reported category to
clinicians who undertook the assessments, this information
was aggregated in a binary variable (White British; other) by
clinical services before data were shared with the research
team. No other details about race and ethnicity were available to the research team.
Clinicians in the stratified care group used a version of the
application that provided a personalized treatment recommendation in real time, recommending either a low- or highintensity treatment based on each patient’s features. These clinicians were trained to discuss this recommendation with
patients following good practice principles of shared
decision-making18 and came to a final treatment allocation decision that was recorded in the application. Clinicians in the
stepped care control group used the application only to enter
data, but they did not receive a personalized recommendation, and they allocated patients to treatment following guidelines for stepped care.1,17 Consistent with these guidelines,
stepped care initially allocates most patients to low-intensity
treatments, but patients with specific disorders (eg, social anxiety disorder, posttraumatic stress disorder, body dysmorphic
disorder) and those who have severe impairment can be referred directly for high-intensity treatments.17 Treatment allocation decisions in routine care are often made after initial
assessment interviews with patients and in consultation with
supervisors or senior clinicians.
Artificial Intelligence Technology
The stratified care application used in this trial is a technology that (1) collects data, (2) processes inputs using a machine learning algorithm, and (3) outputs a personalized treatment recommendation using automated decision rules. The
inputs for the algorithm were patient-reported measures of
jamapsychiatry.com
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depression,19 anxiety,20 functional impairment,21 personality traits,22 employment status, and race and ethnicity. The algorithm calculates an expected prognosis (ie, a probability of
full remission of depression and anxiety symptoms after treatment) based on which cases are classified as standard (better
expected prognosis) or complex (poorer expected prognosis). Standard cases are matched with low-intensity treatments, and patients later have the option to move to highintensity treatment if necessary, whereas complex cases are
matched directly with high-intensity treatments. The rationale is to offer more intensive treatments to patients with
higher risk of poor treatment outcomes, consistent with principles of stratified medicine.13 Further technical details about
the data sources, machine learning approach (LASSO [least absolute shrinkage and selection operator] with optimal scaling), model development, and external cross-validation are
available elsewhere.12 In addition, the stratified care application was programmed to implement decision rules that would
ensure compliance with national clinical guidelines1 for the
treatment allocation of patients with the aforementioned disorders that are treated only with high-intensity psychotherapies in the IAPT program.17 As such, this treatment selection
approach was designed to fast-track 2 groups of patients to
high-intensity treatments: patients with specific conditions for
which only psychotherapy is indicated and patients whose
cases are classified as complex.
Psychological Interventions
After initial assessment interviews, patients accessed their assigned interventions with the first available clinician in each
service (the treating clinician was not the same person as the
assessing clinician). Low-intensity interventions are based on
principles of cognitive behavioral therapy and involve learning coping skills with the support of a qualified psychological
well-being practitioner23 for up to 8 sessions (each lasting 30
minutes). Low-intensity interventions can be delivered as individual-guided self-help, in group settings, or as telephoneguided computerized cognitive behavioral therapy. Highintensity interventions are lengthier (≤20 one-hour sessions)
evidence-based psychotherapies including cognitive behavioral therapy, person-centered experiential counseling for depression, and eye movement desensitization and reprocessing for posttraumatic stress disorder. These interventions were
delivered by clinicians qualified to a postgraduate level, following structured treatment protocols endorsed by national
guidelines,23,24 and under regular supervision (equivalent of
1 h/wk). Consistent with the pragmatic trial design, we did not
record, monitor, or modify these interventions in any way to
preserve the integrity of routinely delivered psychological care.
Training
All participating clinicians attended a 2-hour training course
that covered the study design, informed consent and recruitment tasks, and data collection tasks. Clinicians randomized
to the stratified care group attended 1 additional hour of training (3 hours in total), which covered the stratified care algorithm, its decision-making process, and principles of good practice in shared decision-making18 (discussing treatment options,
(Reprinted) JAMA Psychiatry Published online December 8, 2021
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communicating recommendation, discussing rationale for recommendation, revisiting options, eliciting and addressing
questions or concerns, and codeveloping a plan).
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Figure 1. CONSORT Diagram
32 Eligible clinicians who provided consent

Outcomes
Primary Outcome
The 9-item Patient Health Questionnaire (PHQ-9) is a measure of depression symptoms, where each item is rated on a
Likert scale ranging from 0 to 3 representing symptom frequency in the past 2 weeks, yielding an overall severity score
ranging from 0 to 27.19 The cutoff of at least 10 is recommended to screen for clinically significant depression
symptoms,19 and a change of at least 6 points is indicative of
statistically reliable change.25 Patients in the IAPT program
complete this measure on a session-by-session basis to monitor treatment response.6 Given that treatment duration is variable in routine care, the primary end point was defined at the
time of each patient’s last attended treatment session.
The primary (preregistered) outcome of the study was the
proportion of patients meeting criteria for reliable and clinically significant improvement (RCSI) in the PHQ-9 measure
(posttreatment scores <10 and improved by ≥6 points). Reliable and clinically significant improvement is a clinically stringent and statistically conservative outcome that prioritizes full
remission of symptoms,26 which is important in the context
of stepped care, because patients who do not attain symptomatic remission have the opportunity to access further interventions to attain the best possible outcome. This outcome is
consistent with the stratified care algorithm, which was specifically trained to calculate a prognosis (probability of RCSI)
using this definition, and which was expected to result in better depression (PHQ-9) but not anxiety (Generalized Anxiety
Disorder [GAD-7]) treatment outcomes based on prior
evidence.12
Secondary Outcomes
We compared between-group differences in a range of secondary outcomes of interest. Reliable and clinically significant improvement status in the GAD-720 was examined. Furthermore, IAPT services use an outcome definition termed
reliable recovery, which is a stringent outcome definition that
requires patients to have achieved RCSI in both the PHQ-9 and
GAD-7 measures.17 Additional comparisons examined the proportions of patients who accessed low- vs high-intensity treatments, treatment duration (number of sessions), and treatment dropout (defined as unilateral discontinuation of
treatment before the planned end of treatment). Adherence
to the experimental intervention was measured by comparing the percentage of agreement and interrater reliability (κ statistic) in the stratified care model–recommended vs actual
treatment selection decisions.

Statistical Analysis
Data were analyzed from May 18, 2020, to October 13, 2021.
All analyses followed intention-to-treat principles, and missing (n = 38) posttreatment PHQ-9 and/or GAD-7 scores were imputed with an expectation maximization method using baseline features as predictors. Data analysis was conducted in 5
E4

2 Clinicians excluded
1 Unable to attend training date
1 Left service before trial start
date

30 Clinicians randomized
15 Trial site 1
15 Trial site 2

15 Clinicians allocated to stratified
care

15 Clinicians allocated to stepped
care control

879 Patients screened
583 Eligible
296 Excluded
185 Never attended
111 Ineligible IAPT

574 Patients screened
368 Eligible
206 Excluded
140 Never attended
66 Ineligible IAPT

583 Analyzed patient records
78 Cases with subclinical PHQ-9
scores excluded from primary
end point analysis

368 Analyzed patient records
71 Cases with subclinical PHQ-9
scores excluded from primary
end point analysis

IAPT indicates Improving Access to Psychological Therapies; PHQ-9, 9-item
Patient Health Questionnaire.

steps. First, the proportion of patients with posttreatment remission (RCSI) of depression symptoms (PHQ-9) was compared between groups using logistic regression adjusted for
baseline PHQ-9 scores. A mixed model (clustering by assessing clinician) was estimated first, showing no significant cluster effects (P = .11), so subsequent models applied a parsimonious logistic regression that improved goodness of fit (−2 log
likelihood ratio test, 3262.44 [df = 1]; P < .001). A full output
of the model-building process and goodness-of-fit indices can
be found in eMethods 3 in Supplement 2. Second, logistic regressions were repeated in the subsamples of standard and
complex cases. Third, these analyses were repeated using the
anxiety (GAD-7) outcome measure and IAPT reliable recovery outcome definitions. Fourth, we compared additional secondary outcomes between groups using the χ2 and MannWhitney U tests. Fifth, an economic analysis evaluated the
relative cost-effectiveness of stratified vs stepped care from a
health services perspective using a cost-effectiveness acceptability curve to aid interpretation. Further details about sample
size calculation and economic analyses are provided in
eMethods 2 and 4, respectively, in Supplement 2. Two-sided
P < .05 indicated statistical significance.

Results
The CONSORT diagram is presented in Figure 1. Thirty-two clinicians were recruited from July 5 to October 4, 2018; 2 withdrew before the start of the trial, and 30 were randomly allocated to the stratified care group (n = 15) or a stepped care
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Table 1. Patient Characteristics
Treatment groupa
Characteristic

Full sample (n = 951)

Stratified care (n = 583)

Stepped care (n = 368)

38.27 (14.53)

38.66 (14.61)

37.65 (14.41)

Female

618/950 (65.1)

378/582 (64.9)

240/368 (65.2)

Male

332/950 (34.9)

204/582 (35.1)

128/368 (34.8)

White

906/951 (95.3)

552/583 (94.7)

354/368 (96.2)

Other

45/951 (4.7)

31/583 (5.3)

14/368 (3.8)

187/951 (19.7)

131/583 (22.5)

56/368 (15.2)

Demographics
Age, mean (SD), y
Sex

Race and ethnicityb

Unemployed
Clinical features
Primary diagnosisc
Affective disorder

483/916 (52.7)

303/565 (53.6)

180/351 (51.3)

PTSD

27/916 (2.9)

16/565 (2.8)

11/351 (3.1)

OCD

14/916 (1.5)

6/565 (1.1)

8/351 (2.3)

Anxiety disorder

392/916 (42.8)

240/565 (42.5)

152/351 (43.3)

Prescribed pharmacotherapy

537/924 (58.1)

341/562 (60.7)

196/362 (54.1)

Comorbid long-term medical illnesses

182/932 (19.5)

100/574 (17.4)

82/358 (22.9)

Disability

103/921 (11.2)

61/572 (10.7)

42/349 (12.0)

SAPAS score, mean (SD)d

3.97 (1.43)

4.15 (1.44)

3.70 (1.37)

Complex cases

225/951 (23.7)

160/583 (27.4)

65/368 (17.7)

PHQ-9e

15.47 (5.86)

16.06 (5.69)

14.54 (6.01)

GAD-7f

14.21 (4.65)

14.57 (4.54)

13.64 (4.76)

WSASg

20.33 (9.31)

21.24 (9.22)

18.96 (9.27)

Baseline score, mean (SD)

Abbreviations: GAD-7, Generalized Anxiety Disorder questionnaire;
OCD, obsessive-compulsive disorder; PHQ-9, 9-item Patient Health
Questionnaire; PTSD, posttraumatic stress disorder; SAPAS, Standardised
Assessment of Personality–Abbreviated Scale; WSAS, Work and Social
Adjustment Scale.

supplemented by validated case-finding measures for depression (PHQ-9) and
anxiety disorders (GAD-7). Cases with missing data in each feature were
excluded listwise.
d

Scores range from 0 to 8, with higher scores indicating more personality
disorder traits.

a

Unless otherwise indicated, data are expressed as number/total number (%)
of patients.

e

Scores range from 0 to 27, with higher scores indicating more severe
depression symptoms.

b

Information on race and ethnicity was self-reported by participants but
aggregated in a binary variable (White British; other) by clinical services before
data were shared with the research team. No other details about race and
ethnicity were available to the research team.

f

Scores range from 0 to 21, with higher scores indicating more severe anxiety
symptoms.

g

Scores range from 0 to 40, with higher scores indicating greater impairment
to work and social functioning.

c

Primary diagnosis was determined using a semistructured interview

control group (n = 15). Clinicians in both groups had the same
qualifications and average weekly time availability for assessment tasks. Overall, 1453 patients were screened from August 20, 2018, to February 1, 2019, of whom 951 met eligibility criteria (583 in the stratified care group and 368 controls;
618 women [65.1%] and 332 men [34.9%] among 950 with data
available; mean [SD] age, 38.27 [14.53] years). A small proportion of patients (149 [15.7%]) who did not score above the clinical cutoff in the PHQ-9 were excluded from the primary analysis (focusing on remission of clinically significant symptoms),
but they were included in secondary analyses. Similarly, patients who did not score above the clinical cutoff in the GAD-7
measure (86 [9.0%]) were excluded from that specific analysis, but they were included in other secondary analyses. Detailed sample characteristics are presented in Table 1. In total,
225 of 951 patients (23.7%) were classified by the stratified care
algorithm as complex cases.
jamapsychiatry.com

Table 2 summarizes the results of primary and secondary
outcomes. Overall, in the full sample, patients in the stratified care group had significantly better depression (PHQ-9)
treatment outcomes (RCSI: 264 of 505 [52.3%] vs 134 of 297
[45.1%]; OR, 1.40 [95% CI, 1.04-1.87]; P = .03). Patients in the
stratified care group were also significantly more likely to meet
criteria for IAPT reliable recovery (276 of 573 [48.2%]) after
treatment compared with patients in the stepped care group
(152 of 348 [43.7%]; OR, 1.33 [95% CI, 1.01-1.75]; P = .04). Subgroup analyses indicated that between-group differences in depression outcomes were not significant in the subsample of
complex cases (RCSI: 63 of 160 [39.4%] vs 22 of 65 [33.8%];
OR, 1.28 [95% CI, 0.70-2.35]; P = .42), but they were significant in the subsample of standard cases (RCSI: 201 of 345
[58.3%] vs 112 of 232 [48.3%]; OR, 1.50 [95% CI, 1.07-2.09];
P = .02). Between-group comparisons in the anxiety outcome measure were not statistic ally signific ant (eg,
(Reprinted) JAMA Psychiatry Published online December 8, 2021
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Table 2. Treatment Pathway and Outcomes
Treatment groupa
Characteristic

Stratified care
(n = 583)

Between-group
comparisonsb

Stepped care
(n = 368)

P value

Treatment pathway
LIT

251/583 (43.1)

261/368 (70.9)

HITc

332/583 (56.9)

107/368 (29.1)

Treatment sessions,
mean (SD)

7.10 (5.31)

5.84 (4.15)

Mann-Whitney U test,
121106.00 (SE,
4098.98)

<.001

Treatment dropout

166/542 (30.6)

107/348 (30.7)

χ2 = 0.001

.97

Adherence to the
stratified care model

523/583 (89.7)

233/368 (63.3)

χ2 = 96.41

<.001

0.81

0.22

NA

NA

κ Statistic

χ2 = 70.51

<.001

Treatment outcomes

Abbreviations: GAD-7, Generalized
Anxiety Disorder questionnaire;
HIT, high-intensity treatments;
IAPT, Improving Access to
Psychological Therapies;
LIT, low-intensity treatments;
PHQ-9, 9-item Patient Health
Questionnaire; RCSI, reliable and
clinically significant improvement.
a

Unless otherwise indicated, data are
expressed as number/total number
(%) of patients.

b

Unless otherwise indicated, data are
expressed as odds ratio (95% CI).

c

Of these, 46 (13.9%) had prior LIT in
the stratified care group and 28
(7.6%) had prior LIT in the stepped
care group.

d

Requires patients with case-level
PHQ-9 and/or GAD-7 symptoms to
have (1) attained statistically reliable
improvement on case-level
measures, (2) to have subclinical
symptoms on both measures after
treatment, and (3) to not have
statistically reliable deterioration on
any of these measures after
treatment.

PHQ-9 depression RCSI
Full sample

264/505 (52.3)

134/297 (45.1)

1.40 (1.04-1.87)

.03

Complex cases
subsample

63/160 (39.4)

22/65 (33.8)

1.28 (0.70-2.35)

.42

Standard cases
subsample

201/345 (58.3)

112/232 (48.3)

1.50 (1.07-2.09)

.02

GAD-7 anxiety RCSI
Full sample

266/538 (49.4)

151/327 (46.2)

1.19 (0.90-1.57)

.22

Complex cases
subsample

52/160 (32.5)

21/65 (32.3)

1.02 (0.55-1.89)

.96

Standard cases
subsample

214/378 (56.6)

130/262 (49.6)

1.35 (0.98-1.85)

.07

276/573 (48.2)

152/348 (43.7)

1.33 (1.01-1.75)

.04

IAPT reliable recovery,
full sampled

Figure 2. Treatment Pathways, Costs, and Outcomes in Stratified and Stepped Care

286 (49.1%)

46 Stepped up
(15.5% of LIT cases)

583 Stratified care
Mean treatment cost: £248.48
Probability of full remission of
depression symptoms: 52.3%

297
(50.9%)

79 (21.5%)

Highintensity
treatment
(HIT)

Low-intensity
treatment (LIT)

28 Stepped up
(9.7% of LIT cases)
289
(78.5%)

full-sample RCSI, 266 of 538 [49.4%] vs 151 of 327 [46.2%]; OR,
1.19 [95% CI, 0.90-1.57]; P = .22).
Stratified care was associated with a higher median number of treatment sessions (6 [IQR, 3-9]; range, 1-30) compared with stepped care (5 [IQR, 3-8]; range, 1-25) (MannWhitney U test, 121106.00 [SE, 4098.98]; P < .001). This is
explained by the higher proportion of patients who accessed
high-intensity interventions in stratified care (332 of 583
[56.9%] vs 107 of 368 [29.1%]; χ2 = 70.51; P < .001), because
dropout rates were not significantly different (166 of 542
[30.6%] vs 107 of 348 [30.7%]; χ2 = 0.001; P = .97), but resulted in an approximately 7% increase in the probability of
RCSI. Adherence to the stratified care model was high in the
experimental group (κ = 0.81) and significantly different from
the treatment selection decisions observed in the stepped care
group, which had low concordance with the stratified care algorithm (κ = 0.22). As illustrated in Figure 2, the stratified care
E6

368 Stepped care
Mean treatment cost: £146.45
Probability of full remission of
depression symptoms: 45.1%

To convert costs to US dollars,
multiply pounds sterling by 1.338.

pathway allocated only half of patients (297 of 583 [50.9%])
to low-intensity treatments, whereas most of the patients (289
of 368 [78.5%]) were initially allocated to low-intensity treatments in the stepped care group.
The estimated incremental cost of stratified care was
£104.5 (95% CI, £67.5-£141.6) per patient ($139.83 [95% CI,
$ 9 0.3 2 - $ 1 89. 48] p e r p at i e nt ) ( P < .0 0 1 ) . T h e c o s teffectiveness acceptability curve in Figure 3 shows that the
probability of stratified care being cost-effective, compared
with stepped care, is 50% when the willingness-to-pay
threshold per additional case of reliable improvement is
£1320 ($1766.31). The probability of stratified care being
cost-effective inc reases to 80% and 90% for the
willingness-to-pay values of £2100 ($2810.03) and £3050
($4081.24), respectively. Further details of the economic
analysis are available in eMethods 4 and eFigures 1 and 2 in
Supplement 2.
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Figure 3. Cost-effectiveness Acceptability Curve

Probability of stratified care being cost-effective, %

100

80

60

40

20

0
0

2000

4000

6000

8000

10 000

WTP per case of reliable improvement, GBP

Probability of stratified care being cost-effective (vs stepped care) is greater
than 50% if the willingness-to-pay (WTP) threshold is greater than £1320
($1766.31) per additional case of reliable improvement (dashed lines).
GBP indicates pound sterling currency.

Discussion
A growing literature in the field of depression suggests that treatment outcomes could be improved through personalized treatment selection.27 The findings of this trial indicate that stratified
care improves depression outcomes, albeit at an incremental cost
per treatment. This improvement comes with no effect on dropout rates, despite the fact that significantly more patients in the
stratified care group accessed high-intensity treatments, which
have longer waiting lists. Dropout rates in the present study and
across both trial arms (approximately 30%) were consistent with
data from IAPT services.7 Furthermore, the stratified care model
was feasible to implement and had a high adherence rate
(κ= 0.81). Treatment selection decisions made in the stepped care
group had nearly chance-level convergence with those in the
stratified care algorithm (κ= 0.22), indicating that decisionmaking across these models is highly distinctive. Stratified care
also increased the efficiency of initial assessments, because clinicians in the experimental group were able to assess a larger
sample of patients in the same allotted weekly time, whereas decisions in the stepped care group were sometimes protracted by
the need to consult with colleagues or supervisors about suitability for available treatments, which is commonplace in stepped
care.23
As expected, the proportions of patients with full remission (RCSI) of depression and anxiety symptoms were higher
in stratified care compared with stepped care, but differences
were statistically significant only in the PHQ-9 measure. This
is consistent with prior evidence suggesting that stratified care
could improve remission rates in the PHQ-9 but not in the GAD-7
measure.12 A plausible explanation is that there was little difference in the treatment allocation of patients with anxiety disorders between stratified and stepped care, because both models refer patients with some conditions (eg, posttraumatic stress
jamapsychiatry.com

disorder) directly to high-intensity treatments in line with clinical guidelines.1,17 These results are consistent with prior evidence that IAPT services that have a higher proportion of patients accessing high-intensity treatments tend to have better
treatment outcomes.17,25 Related to this point, a possible explanation for the observed effect may be owing to an absolute
increase in the proportion of patients allocated to highintensity treatment, rather than a strategic matching effect.
Future implementation trials could examine whether the effect of stratified treatment selection varies across IAPT services, with variable proportions of patients allocated to highintensity treatment.
Contrary to our expectations, only standard (ie, less complex) cases had significantly better outcomes in stratified care.
In the present study, relatively few patients with the poorest expected prognosis were classified as complex cases (225 of 951
[23.7%]), and it may be that the observed trend toward better
outcomes in stratified care for the complex cases could be diluted by the inclusion of some patients with chronic conditions that simply do not respond to interventions available in
IAPT services. Previous research28 suggests that the presence
of patients with chronic conditions in a clinical sample may obscure the differential treatment response in those with more
treatable conditions. It is, of course, possible that stratified care
does not work for complex cases as defined in this study, and
future research should consider how to improve outcomes for
those at the highest risk of poor treatment response.

Limitations
The pragmatic trial design maximized feasibility, sample size,
and external validity to the routine care context, but inevitably
had some weaknesses in terms of internal validity. Outcomes
were patient reported, and no formal diagnostic interviews or
observer-rated outcomes were available. The sole reliance on
patient-reported measures means that we cannot rule out or examine the potential influence of biases such as motivated responding and social desirability bias. Although the PHQ-9 and
GAD-7 measures are relevant to the broad range of affective and
anxiety symptoms reported by participants, a significant limitation is that disorder-specific measures were unavailable for
conditions such as posttraumatic stress disorder and obsessivecompulsive disorder. In addition, most of the participants were
White individuals, which limits the generalizability of these findings to other racial and ethnic minority groups. Furthermore,
outcomes were defined at the last attended treatment session,
and therefore the maintenance of these effects over a longer time
frame could not be established. A further implication is that, on
average, the final outcomes in the stratified care group were measured at a later time compared with those in stepped care, because more patients had lengthier high-intensity treatments in
the experimental group. Thus, there are uncertainties related
to the pragmatic design, and future studies could establish a fixed
follow-up measurement schedule to understand short- and
longer-term effects with greater precision. The economic analysis was limited to a comparative examination of acute-phase
treatment costs, but wider outcomes such as quality-adjusted
life-years and use of health services after the end of treatment
remain unknown.
(Reprinted) JAMA Psychiatry Published online December 8, 2021
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Conclusions
Overall, the present findings indicate that stratified care is
feasible to implement in routine IAPT services, improving
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the efficiency and precision of psychological assessments
in a way that preserves shared decision-making. Implementation of stratified care resulted in better depression
treatment outcomes albeit with an additional cost per treatment.
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